The Venous Thrombotic Risk in Non-Surgical Patients: Epidemiological Data and Efficacy/Safety Profile of a Low-Molecular-Weight Heparin (Enoxaparin)

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 49-56

  Wagner, T ^b   Halbritter, R ^g   Flosbach, C W ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE   (Germany)

^c NONE   (Germany)

^d NONE   (Germany)

^e NONE   (Germany)

^f NONE   (Germany)

^g NONE   (Germany)

Author keywords

Epidemiology; Low molecular weight heparin; Medical patients; Thrombosis prophylaxis; Unfractionated heparin; Venous thrombosis

Indexed keywords

ENOXAPARIN; HEPARIN CALCIUM;

ADULT; AGED; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; RISK FACTORS; THROMBOPHLEBITIS;

EID: 9044240038     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217272     Document Type: Article

References (23)

1. Gelmers HJ: Effects of low-dose subcutaneous heparin on the occurrence of deep vein thrombosis in patients with ischemic stroke. Acta Neurol Scand 1980:61:313-318.
2. Czcchanowski B. Heinrich F: Prophylaxe venöser Thrombosen bei frischem ischämischen zerebrovas-kulärcn Insult. Dtsch Med Wo-chenschr 1981;106:1254-1260.
3. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM. Powers PJ. Andrew M, Magnani HN, Hull RD. Gent M: Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;i:523-526.
4. Prins MH, Gelsema R. Sing AK, van Heerde LR, Ottolandcr GJH: Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin®) in stroke patients. Haemostasis 1989; 19:245-250.
5. Oczkowski WJ, Ginsberg JS, Shin A, Panju A: Venous thromboembolism in patients undergoing rehabilitation for stroke. Arch Phys Med Rehabil 1992;73:712-716.
6. Cade JF: High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-450.
7. Dalian R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segres-taa JM: Prevention of deep vein thrombosis in elderly medical inpatients by a low molecular weight heparin: A randomized doubleblind trial. Haemostasis 1986; 16: 159-164.
8. Poniewierki M, Barthels M, Kuhn M, Poliwoda H: Über die Wirksamkeit niedermolekularen Heparins (Fragmin) in der Thromboembolieprophylaxe bei internistischen Patienten: Eine randomisierte Doppelblindstudie. Med Klin 1988:83: 241-245.
9. Maurer BJ. Wray R, Shillingford JP: Frequency of venous thrombosis after myocardial infarction. Lancet 1971;ii: 1385-1387.
10. Handley AJ: Low-dose heparin after myocardial infarction. Lancet 1972; ii:623-624.
11. Handley AJ, Emerson PA, Fleming PR: Heparin in the prevention of deep vein thrombosis after myocardial infarction. Br Med J 1972;ii: 436-438.
12. Warlow C. Beattie AG. Terry G. Ogston D, Kenmure ACF. Douglas AS: A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973;ii:934-936.
13. Emerson PA, Marks P: Prevention of thromboembolism after myocardial infarction: Effect of low-dose heparin or smoking. Br Med J 1977; 264:18-20.
14. Pitt A, Anderson ST, Habersberger PG, Rosengarten DS: Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. Am Heart J 1980;99:574-578.
15. Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM: Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-117.
16. Kierkegaard A, Norgren L, Olson CG, Castenfars J, Persson G. Pers-son S: Incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 1987;222: 409-414.
17. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ: Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977;ii:800-801.
18. Harenberg J. Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubier W. Heene DL: Randomized controlled study of heparin and low molecular weight heparin for prevention of dccp-vcin thrombosis in medical patients. Thromb Res 1990; 59:639-650.
19. Harenberg J. Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL. and the HESIM group: Heparin study in internal medicine (HESIM): Design and preliminary results. Thromb Res 1992;68:33-43.
20. Harenberg J, Roebruck P, Heinrich R, Schmitz-Hübner U, Heene DL. and the Heparin Study in Internal Medicine Group: A randomized double blind trial of low molecular weight heparin for prophylaxis of thromboembolism in medical inpatients (abstract 380). Thromb Hae-most 1993:69:648.
21. Jongbloets LMM, Lensing AWA, Büllcr HR, ten Cate JW: The value of real-time compression ultrasound in detecting deep-vein thrombosis in asymptomatic high-risk patients (abstract C88). Thromb Res 1992; 65(suppl 1):46.
22. Weinmann EE. Salzman EW: Deep-vein thrombosis. N Engl J Med 1994;331:1630-1641.
23. Bounameaux H, de Moerloosc P, Perrier A, Rcber G: Plasma measurement of D-Dimcr as diagnostic aid in suspected venous thromboembolism: An overview. Thromb Haemost 1994:71:1-6.